Deals & Cases
Rights offering of Swiss listed mondoBIOTECH
mondoBIOTECH (SIX Swiss Exchange: RARE), an internet-based biotech research company engaged in the discovery and development of medicinal product candidates for use in the treatment of rare and neglected diseases, conducted its second non-underwritten rights offering in 2010, with shares not taken up in the rights offering to be placed privately with selected investors in and outside Switzerland.
Lenz & Staehelin advised mondoBIOTECH in this transaction and also acted as listing agent vis-à-vis SIX Swiss Exchange. The team was led by Patrick Schleiffer and included Urs Reinwald, Stefan Schwaller (Tax), Patrick Schärli and Sascha Krüsi.